Abstract
Population-based studies have demonstrated that an increasing number of incidental thyroid nodules are being identified. The corresponding increase in thyroid-based diagnostic procedures, such as fine-needle aspiration biopsy, has in part led to an increase in the diagnoses of thyroid cancers and to more thyroid surgeries being performed. Small papillary thyroid cancers account for most of this increase in diagnoses. These cancers are considered to be low risk because of the excellent patient outcomes, with a 5-year disease-specific survival of >98%. As a result, controversy remains regarding the optimal management of newly diagnosed differentiated thyroid cancer, as the complications related to thyroidectomy (primarily recurrent laryngeal nerve injury and hypoparathyroidism) have considerable effects on patient quality of life. This Review highlights current debates, including undertaking active surveillance versus thyroid surgery for papillary thyroid microcarcinoma, the extent of thyroid surgery and lymphadenectomy for low-risk differentiated thyroid cancer, and the use of molecular testing to guide decision-making about whether surgery is required and the extent of the initial operation. This Review includes a discussion of current consensus guideline recommendations regarding these topics in patients with differentiated thyroid cancer. Additionally, innovative thyroidectomy techniques (including robotic and transoral approaches) are discussed, with an emphasis on patient preferences around decision-making and outcomes following thyroidectomy.
Key points
-
The incidence of thyroid cancer is increasing across the United States; this includes thyroid cancers of all tumour sizes and stages.
-
Molecular testing for indeterminate thyroid nodules continues to evolve and guide recommendations for the extent of thyroid surgery.
-
Appropriate extent of thyroidectomy for patients with low-risk thyroid cancer remains dynamic and might include active surveillance, thyroid lobectomy or total thyroidectomy.
-
Given the excellent outcomes for most patients with differentiated thyroid cancer, patient preference and a robust discussion regarding options for the extent of surgery and long-term surveillance are critical.
-
A strong association exists between surgeon volume and patient outcomes; surgeons’ awareness of their own outcomes is critical.
-
Referring providers, payers and policymakers should be aware of the implications of the association between surgeon volume and patient outcomes so that patient access to experienced thyroid surgeons can be optimized.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Davies, L. & Welch, H. G. Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head Neck Surg. 140, 317–322 (2014).
Kitahara, C. M. & Sosa, J. A. The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12, 646–653 (2016).
Davies, L. et al. American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: the increasing incidence of thyroid cancer. Endocr. Pract. 21, 686–696 (2015).
Cabanillas, M. E., McFadden, D. G. & Durante, C. Thyroid cancer. Lancet 388, 2783–2795 (2016).
Lubitz, C. C. & Sosa, J. A. The changing landscape of papillary thyroid cancer: epidemiology, management, and the implications for patients. Cancer 122, 3754–3759 (2016).
Sosa, J. A., Hanna, J. W., Robinson, K. A. & Lanman, R. B. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery 154, 1420–1426; discussion 1426–1427 (2013).
Kent, W. D. et al. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ 177, 1357–1136 (2007).
Enewold, L. et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol. Biomarkers Prev. 18, 784–791 (2009).
Tuttle, R. M. et al. in AJCC Cancer Staging Manual 8th edn Ch. 73 (ed. Amin, M. B.) 873–890 (Springer Nature, 2017).
Tuttle, R. M., Haugen, B. & Perrier, N. D. Updated American Joint Committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid 27, 751–756 (2017).
Cibas, E. S. & Ali, S. Z. The Bethesda system for reporting thyroid cytopathology. Thyroid 19, 1159–1165 (2009).
Cibas, E. S. & Ali, S. Z. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 27, 1341–1346 (2017).
Haugen, B. R. et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016).
Ferris, R. L. et al. American Thyroid Association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision Making. Thyroid 25, 760–768 (2015).
Yip, L. & Sosa, J. A. Molecular-directed treatment of differentiated thyroid cancer: advances in diagnosis and treatment. JAMA Surg. 151, 663–670 (2016).
Nikiforov, Y. E. Role of molecular markers in thyroid nodule management: then and now. Endocr. Pract. 23, 979–988 (2017).
McIver, B. et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. J. Clin. Endocrinol. Metab. 99, 4069–4077 (2014).
Harrison, G., Sosa, J. A. & Jiang, X. Evaluation of the Afirma gene expression classifier in repeat indeterminate thyroid nodules. Arch. Pathol. Lab Med. 141, 985–989 (2017).
Alexander, E. K. et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N. Engl. J. Med. 367, 705–715 (2012).
Duh, Q. Y., Busaidy, N. L., Rahilly-Tierney, C., Gharib, H. & Randolph, G. A. Systematic review of the methods of diagnostic accuracy studies of the Afirma gene expression classifier. Thyroid 27, 1215–1222 (2017).
Valderrabano, P. et al. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur. J. Endocrinol. 174, 621–629 (2016).
Marti, J. L. et al. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules. Ann. Surg. Oncol. 22, 3996–4001 (2015).
Harrell, R. M. & Bimston, D. N. Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology. Endocr. Pract. 20, 364–369 (2014).
Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014).
Steward, D. et al. Clinical validation of Thyroseq V3 performance in thyroid nodules with indeterminate cytology: a prospective blinded multi-institutional validation study. Thyroid 27, A167 (2017).
Brauner, E. et al. Performance of the Afirma gene expression classifier in Hurthle cell thyroid nodules differs from other indeterminate thyroid nodules. Thyroid 25, 789–796 (2015).
Duh, Q. Y. et al. Development and validation of classifiers to enhance the Afirma genomic sequencing classifier performance among Hurthle cell specimens. Thyroid 27, A168 (2017).
Strickland, K. C. et al. Preoperative cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a prospective analysis. Thyroid 26, 1466–1471 (2016).
Sahli, Z. T., Umbricht, C. B., Schneider, E. B. & Zeiger, M. A. Thyroid nodule diagnostic markers in the face of the new NIFTP category: time for a reset? Thyroid 27, 1393–1399 (2017).
Balentine, C. J., Vanness, D. J. & Schneider, D. F. Cost-effectiveness of lobectomy versus genetic testing (Afirma(R)) for indeterminate thyroid nodules: considering the costs of surveillance. Surgery 163, 88–96 (2018).
Yip, L. et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J. Clin. Endocrinol. Metab. 97, 1905–1912 (2012).
Carneiro-Pla, D. et al. Feasibility of surgeon-performed transcutaneous vocal cord ultrasonography in identifying vocal cord mobility: a multi-institutional experience. Surgery 156, 1597–1602; discussion 1602–1594 (2014).
Chandrasekhar, S. S. et al. Clinical practice guideline: improving voice outcomes after thyroid surgery. Otolaryngol. Head Neck Surg. 148, S1–S37 (2013).
Renkema, K. Y., Alexander, R. T., Bindels, R. J. & Hoenderop, J. G. Calcium and phosphate homeostasis: concerted interplay of new regulators. Ann. Med. 40, 82–91 (2008).
Holick, M. F. Vitamin D deficiency. N. Engl. J. Med. 357, 266–281 (2007).
Momesso, D. P. et al. Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine. J. Clin. Endocrinol. Metab. 101, 2692–2700 (2016).
Yeh, M. W. et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid 25, 3–14 (2015).
American Thyroid Association Surgery Working, G. et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 19, 1153–1158 (2009).
National Comprehensive Cancer Network. Thyroid Carcinoma Version 2. May 2017 https://www.nccn.org/professionals/physician_gls/default.aspx (2017).
Padovani, R. P. et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. Thyroid 22, 926–930 (2012).
Sohn, S. Y. et al. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. Thyroid 24, 872–877 (2014).
Hay, I. D. et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 144, 980–987; discussion 987–988 (2008).
Ito, Y. et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J. Surg. 34, 28–35 (2010).
Baudin, E. et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 83, 553–559 (1998).
Wang, T. S., Goffredo, P., Sosa, J. A. & Roman, S. A. Papillary thyroid microcarcinoma: an over-treated malignancy? World J. Surg. 38, 2297–2303 (2014).
Ito, Y. et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 24, 27–34 (2014).
Bilimoria, K. Y. et al. Extent of surgery affects survival for papillary thyroid cancer. Ann. Surg. 246, 375–381; discussion 381–374 (2007).
Haigh, P. I., Urbach, D. R. & Rotstein, L. E. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann. Surg. Oncol. 12, 81–89 (2005).
Barney, B. M., Hitchcock, Y. J., Sharma, P., Shrieve, D. C. & Tward, J. D. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 33, 645–649 (2011).
Mendelsohn, A. H., Elashoff, D. A., Abemayor, E. & St John, M. A. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch. Otolaryngol. Head Neck Surg. 136, 1055–1061 (2010).
Nixon, I. J. et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 151, 571–579 (2012).
Adam, M. A. et al. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J. Clin. Endocrinol. Metab. 100, 115–121 (2015).
Adam, M. A. et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann. Surg. 260, 601–605; discussion 605–607 (2014).
Tuttle, R. M. et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol. Head Neck Surg. 143, 1015–1020 (2017).
Hughes, D. T. et al. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148, 1100–1106; discussion 1006–1107 (2010).
Hughes, D. T. & Doherty, G. M. Central neck dissection for papillary thyroid cancer. Cancer Control 18, 83–88 (2011).
Adam, M. A. et al. Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J. Clin. Oncol. 34, 4415–4420 (2016).
Lang, B. H. et al. A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid 23, 1087–1098 (2013).
Viola, D. et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J. Clin. Endocrinol. Metab. 100, 1316–1324 (2015).
Wang, T. S., Cheung, K., Farrokhyar, F., Roman, S. A. & Sosa, J. A. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann. Surg. Oncol. 20, 3477–3483 (2013).
Wang, T. S., Evans, D. B., Fareau, G. G., Carroll, T. & Yen, T. W. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer. Ann. Surg. Oncol. 19, 4217–4222 (2012).
Carling, T. et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 22, 237–244 (2012).
American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009).
Cooper, D. S. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16, 109–142 (2006).
Schneider, D. F., Chen, H. & Sippel, R. S. Impact of lymph node ratio on survival in papillary thyroid cancer. Ann. Surg. Oncol. 20, 1906–1911 (2013).
Robinson, T. J. et al. How many lymph nodes are enough? Assessing the adequacy of lymph node yield for papillary thyroid cancer. J. Clin. Oncol. 34, 3434–3439 (2016).
Jiang, Z. G. et al. Clinical benefits of scarless endoscopic thyroidectomy: an expert’s experience. World J. Surg. 35, 553–557 (2011).
Wilhelm, T. & Metzig, A. Endoscopic minimally invasive thyroidectomy (eMIT): a prospective proof-of-concept study in humans. World J. Surg. 35, 543–551 (2011).
Anuwong, A. Transoral endoscopic thyroidectomy vestibular approach: a series of the first 60 human cases. World J. Surg. 40, 491–497 (2016).
Kandil, E. H., Noureldine, S. I., Yao, L. & Slakey, D. P. Robotic transaxillary thyroidectomy: an examination of the first one hundred cases. J. Am. Coll. Surg. 214, 558–564; discussion 564–556 (2012).
Duke, W. S. et al. Remote access robotic facelift thyroidectomy: a multi-institutional experience. World J. Surg. 41, 116–121 (2017).
Lee, J., Kwon, I. S., Bae, E. H. & Chung, W. Y. Comparative analysis of oncological outcomes and quality of life after robotic versus conventional open thyroidectomy with modified radical neck dissection in patients with papillary thyroid carcinoma and lateral neck node metastases. J. Clin. Endocrinol. Metab. 98, 2701–2708 (2013).
Kim, M. J. et al. Yonsei Experience of 5000 gasless transaxillary robotic thyroidectomies. World J. Surg. 42, 393–401 (2018).
Berber, E. et al. American Thyroid Association statement on remote-access thyroid surgery. Thyroid 26, 331–337 (2016).
Lang, B. H., Wong, C. K., Tsang, J. S., Wong, K. P. & Wan, K. Y. A systematic review and meta-analysis comparing surgically-related complications between robotic-assisted thyroidectomy and conventional open thyroidectomy. Ann. Surg. Oncol. 21, 850–861 (2014).
Adam, M. A. et al. Robotic thyroidectomy for cancer in the US: patterns of use and short-term outcomes. Ann. Surg. Oncol. 21, 3859–3864 (2014).
Anuwong, A., Kim, H. Y. & Dionigi, G. Transoral endoscopic thyroidectomy using vestibular approach: updates and evidences. Gland Surg. 6, 277–284 (2017).
Chung, T. K. et al. Examining national outcomes after thyroidectomy with nerve monitoring. J. Am. Coll. Surg. 219, 765–770 (2014).
Dralle, H. et al. Intraoperative monitoring of the recurrent laryngeal nerve in thyroid surgery. World J. Surg. 32, 1358–1366 (2008).
Brajcich, B. C. & McHenry, C. R. The utility of intraoperative nerve monitoring during thyroid surgery. J. Surg. Res. 204, 29–33 (2016).
Pisanu, A., Porceddu, G., Podda, M., Cois, A. & Uccheddu, A. Systematic review with meta-analysis of studies comparing intraoperative neuromonitoring of recurrent laryngeal nerves versus visualization alone during thyroidectomy. J. Surg. Res. 188, 152–161 (2014).
Barczynski, M., Konturek, A. & Cichon, S. Randomized clinical trial of visualization versus neuromonitoring of recurrent laryngeal nerves during thyroidectomy. Br. J. Surg. 96, 240–246 (2009).
Dralle, H. et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 136, 1310–1322 (2004).
Henry, B. M. et al. The current state of intermittent intraoperative neural monitoring for prevention of recurrent laryngeal nerve injury during thyroidectomy: a PRISMA-compliant systematic review of overlapping meta-analyses. Langenbecks Arch. Surg. 402, 663–673 (2017).
Fundakowski, C. E. et al. Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society consensus statement. Head Neck 40, 663–675 (2018).
Terris, D. J., Chaung, K. & Duke, W. S. Continuous vagal nerve monitoring is dangerous and should not routinely be done during thyroid surgery. World J. Surg. 39, 2471–2476 (2015).
Dralle, H. et al. Loss of the nerve monitoring signal during bilateral thyroid surgery. Br. J. Surg. 99, 1089–1095 (2012).
Dionigi, G. & Frattini, F. Staged thyroidectomy: time to consider intraoperative neuromonitoring as standard of care. Thyroid 23, 906–908 (2013).
Fontenot, T. E., Randolph, G. W., Setton, T. E., Alsaleh, N. & Kandil, E. Does intraoperative nerve monitoring reliably aid in staging of total thyroidectomies? Laryngoscope 125, 2232–2235 (2015).
Al-Qurayshi, Z., Kandil, E. & Randolph, G. W. Cost-effectiveness of intraoperative nerve monitoring in avoidance of bilateral recurrent laryngeal nerve injury in patients undergoing total thyroidectomy. Br. J. Surg. 104, 1523–1531 (2017).
Randolph, G. W. et al. Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope 121 (Suppl. 1), S1–S16 (2011).
Barczynski, M. et al. External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope 123 (Suppl. 4), S1–S14 (2013).
Terris, D. J. et al. American Thyroid Association statement on outpatient thyroidectomy. Thyroid 23, 1193–1202 (2013).
Snyder, S. K. et al. Outpatient thyroidectomy is safe and reasonable: experience with more than 1,000 planned outpatient procedures. J. Am. Coll. Surg. 210, 575–582, 582–574 (2010).
Segel, J. M., Duke, W. S., White, J. R., Waller, J. L. & Terris, D. J. Outpatient thyroid surgery: safety of an optimized protocol in more than 1,000 patients. Surgery 159, 518–523 (2016).
Begg, C. B., Cramer, L. D., Hoskins, W. J. & Brennan, M. F. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 280, 1747–1751 (1998).
Birkmeyer, J. D. et al. Hospital volume and surgical mortality in the United States. N. Engl. J. Med. 346, 1128–1137 (2002).
Gould, J. C. et al. Perioperative safety and volume: outcomes relationships in bariatric surgery: a study of 32,000 patients. J. Am. Coll. Surg. 213, 771–777 (2011).
Mitchell, J. et al. Avoidable reoperations for thyroid and parathyroid surgery: effect of hospital volume. Surgery 144, 899–906; discussion 906–897 (2008).
Sosa, J. A. et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann. Surg. 228, 320–330 (1998).
Stavrakis, A. I., Ituarte, P. H., Ko, C. Y. & Yeh, M. W. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery 142, 887–899; discussion 887–899 (2007).
Boudourakis, L. D., Wang, T. S., Roman, S. A., Desai, R. & Sosa, J. A. Evolution of the surgeon-volume, patient-outcome relationship. Ann. Surg. 250, 159–165 (2009).
Kandil, E., Noureldine, S. I., Abbas, A. & Tufano, R. P. The impact of surgical volume on patient outcomes following thyroid surgery. Surgery 154, 1346–1352; discussion 1352–1343 (2013).
Tuggle, C. T., Park, L. S., Roman, S., Udelsman, R. & Sosa, J. A. Rehospitalization among elderly patients with thyroid cancer after thyroidectomy are prevalent and costly. Ann. Surg. Oncol. 17, 2816–2823 (2010).
Sosa, J. A. et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J. Clin. Endocrinol. Metab. 93, 3058–3065 (2008).
Grogan, R. H. et al. A population-based prospective cohort study of complications after thyroidectomy in the elderly. J. Clin. Endocrinol. Metab. 97, 1645–1653 (2012).
Hauch, A., Al-Qurayshi, Z., Randolph, G. & Kandil, E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann. Surg. Oncol. 21, 3844–3852 (2014).
Adam, M. A. et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann. Surg. 265, 402–407 (2017).
Cox, C. et al. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines? Surgery 163, 75–80 (2018).
Kebebew, E., Duh, Q. Y. & Clark, O. H. Total thyroidectomy or thyroid lobectomy in patients with low-risk differentiated thyroid cancer: surgical decision analysis of a controversy using a mathematical model. World J. Surg. 24, 1295–1302 (2000).
Liu, J. B. et al. Variation of thyroidectomy-specific outcomes among hospitals and their association with risk adjustment and hospital performance. JAMA Surg. 153, e174593 (2017).
Lim, H., Devesa, S. S., Sosa, J. A., Check, D. & Kitahara, C. M. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317, 1338–1348 (2017).
Lithwick-Yanai, G. et al. Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears. J. Clin. Pathol. 70, 500–507 (2017).
Labourier, E. et al. Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. J. Clin. Endocrinol. Metab. 100, 2743–2750 (2015).
Acknowledgements
J.A.S. is a member of the Data Monitoring Committee of the Medullary Thyroid Cancer Consortium Registry supported by Novo Nordisk, GlaxoSmithKline, Astra-Zeneca and Eli Lilly.
Author information
Authors and Affiliations
Contributions
T.S.W. researched the data for the article. T.S.W. and J.A.S. both provided substantial contribution to the discussion of the content, wrote the article and reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Active surveillance
-
A management approach that can be an alternative to immediate surgery in patients with low-risk thyroid cancer.
- Positive predictive value
-
The proportion of positive results that are true positive results.
- Negative predictive value
-
The proportion of negative results that are true negative results.
- Sensitivity
-
The proportion of positive tests that are correctly identified as positive.
- Specificity
-
The proportion of negative tests that are correctly identified as negative.
- Hürthle cell neoplasm
-
A tumour of the thyroid gland composed of Hürthle cells.
- Hilum
-
The depressed area of the surface of a lymph node through which lymphatics and blood vessels enter and exit the node.
- Lymph node ratio
-
The number of metastatic lymph nodes divided by the total number of lymph nodes removed.
Rights and permissions
About this article
Cite this article
Wang, T.S., Sosa, J.A. Thyroid surgery for differentiated thyroid cancer — recent advances and future directions. Nat Rev Endocrinol 14, 670–683 (2018). https://doi.org/10.1038/s41574-018-0080-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-018-0080-7
This article is cited by
-
Real-time imaging of ipsilateral parathyroid glands by retrograde injection of methylene blue into the superior thyroid artery: a new intraoperative parathyroid protection method
BMC Surgery (2024)
-
An integrated model incorporating deep learning, hand-crafted radiomics and clinical and US features to diagnose central lymph node metastasis in patients with papillary thyroid cancer
BMC Cancer (2024)
-
Incidental thyroid carcinoma in an endemic goiter area in Italy: histopathological features and predictors of a common finding
Endocrine (2024)
-
MicroRNA-181b-5p Facilitates Thyroid Cancer Growth via Targeting Programmed Cell Death 4
Molecular Biotechnology (2024)
-
Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool
World Journal of Surgical Oncology (2023)